Panthera Biopartners has experienced a resurgence in its oncology clinical trial division following its reopening earlier this year. The company has been selected by two large pharmaceutical companies to conduct oncology trials at its UK-based sites.
 
Panthera’s oncology division was previously forced to close due to its association with the Rutherford Specialist Cancer clinics, which underwent administration. However, the company has since expanded its existing clinical trial sites to accommodate immunotherapy and hormone therapy oncology trials and has assembled a team of experienced oncologists as principal investigators (PIs).
 
Chris Dodd, Chief Commercial Officer at Panthera, commented: “There is a great shortage of top quality oncology clinical trial sites with experienced oncology specialists across the world. The UK is particularly well placed to become a center for running commercial oncology trials with top-quality PIs, a diverse population and experienced clinical trial sites. We were very successful in attracting oncology studies to the UK. With our clinics set up to run these trials and a team of world-class oncology specialists, we are well on our way to re-establishing Panthera as a major player in this area.”
 
Panthera operates six dedicated clinical trial sites across the UK, located in Glasgow, York, Sheffield, Preston, Rochdale, and Enfield. The company conducts clinical trials for pharmaceutical companies, biotechs, and contract research organizations across a variety of therapeutic areas, including vaccines, cardiovascular, general medicine, neurology, respiratory, and rheumatology.